Abstract
We have demonstrated that RNA-dependent protein kinase (PKR) and its downstream protein p-eIF2α are independent prognostic markers for overall survival in lung cancer. In the current study, we further investigate the interaction between PKR and AMPK in lung tumor tissue and cancer cell lines. We examined PKR protein expression in 55 frozen primary lung tumor tissues by Western blotting and analyzed the association between PKR expression and expression of 139 proteins on tissue samples examined previously by Reverse Phase Protein Array (RPPA) from the same 55 patients. We observed that biomarkers were either positively (phosphorylated AMP-activated kinase(T172) [p-AMPK]) or negatively (insulin receptor substrate 1, meiotic recombination 11, ATR interacting protein, telomerase, checkpoint kinase 1, and cyclin E1) correlated with PKR. We further confirmed that induction of PKR with expression vectors in lung cancer cells causes activation of the AMPK protein independent of the LKB1, TAK1, and CaMKKβ pathway. We found that PKR causes nutrient depletion, which increases AMP levels and decreases ATP levels, causing AMPK phosphorylation. We further demonstrated that inhibiting AMPK expression with compound C or siRNA enhanced PKR-medi...Continue Reading
References
Mar 10, 2001·Apoptosis : an International Journal on Programmed Cell Death·J Gil, M Esteban
Apr 21, 2001·Cell Death and Differentiation·G N Barber
Sep 6, 2002·Oncogene·Stephan A VorburgerKelly K Hunt
Feb 13, 2004·International Journal of Cancer. Journal International Du Cancer·Su Ing HiiNigel A J McMillan
Oct 6, 2004·The Biochemical Journal·Hamid R SamariPer O Seglen
Apr 27, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Abujiang PataerStephen G Swisher
Sep 13, 2005·Surgery·Urs von HolzenStephen G Swisher
Jul 11, 2006·Annual Review of Cell and Developmental Biology·Sheila A Stewart, Robert A Weinberg
Apr 25, 2007·Biochimie·M A GarcíaM Esteban
Jan 18, 2008·Cancer Research·Regan M MemmottPhillip A Dennis
Dec 11, 2008·The Journal of Pharmacology and Experimental Therapeutics·Wenxian HuStephen G Swisher
Feb 25, 2009·Nature Reviews. Cancer·Marcos Malumbres, Mariano Barbacid
Jul 28, 2009·Nature·Yibin DengSandy Chang
Feb 9, 2010·PLoS Genetics·Lakxmi Subramanian, Toru M Nakamura
Oct 12, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Abujiang PataerStephen G Swisher
Mar 25, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W N WilliamH-Y Lee
Sep 23, 2011·Genes & Development·D Grahame Hardie
Nov 11, 2011·Cold Spring Harbor Symposia on Quantitative Biology·D G Hardie
Nov 22, 2011·PloS One·Yong HeApar Pataer
Jan 17, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Li-nian HuangWei Jia
Feb 22, 2012·PloS One·Yong HeBingliang Fang
Mar 23, 2012·Nature Reviews. Molecular Cell Biology·D Grahame HardieSimon A Hawley
Jun 5, 2012·Nature·Sang-Min JeonNissim Hay
Feb 16, 2013·Cancer Cell·D Grahame Hardie
May 18, 2013·Cancer Cell·John E Burke, Roger L Williams
May 28, 2013·Cell·Gabriel LeprivierPoul H Sorensen
Jul 19, 2013·Oncology·Jong Gwang KimSu-Jin Kim
Jan 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W N WilliamH-Y Lee
Citations
Oct 23, 2016·Oncotarget·Chuncheng HaoApar Pataer
Aug 11, 2016·Oncotarget·Fangfang DuanJianxin Gu
Sep 27, 2019·Oncogene·Apar PataerStephen G Swisher
Oct 8, 2016·Oncotarget·Ji ChengKaixiong Tao